Literature DB >> 1677299

A comparison of excitotoxic lesions of the basal forebrain by kainate, quinolinate, ibotenate, N-methyl-D-aspartate or quisqualate, and the effects on toxicity of 2-amino-5-phosphonovaleric acid and kynurenic acid in the rat.

P Winn1, T W Stone, M Latimer, M H Hastings, A J Clark.   

Abstract

1. It has been suggested that an NMDA1 receptor subtype might be activated by N-methyl-D-aspartate (NMDA) and ibotenate and an NMDA2 subtype by NMDA or quinolinate, and that the NMDA2 site might be more susceptible to blockade by kynurenic acid. 2. Experiments were carried out to examine the ability of 2-amino-5-phosphonovaleric acid (AP5) and kynurenic acid to antagonize the neurotoxic properties of kainate, ibotenate, NMDA, quinolinate and quisqualate injected into the rat basal forebrain. 3. Following histological analysis of the injection sites, lesion volume was assessed parametrically. Each of the toxins except quisqualate was found to make lesions of parvocellular neurones within the basal forebrain with a relative order of potency: kainate much greater than quinolinate greater than ibotenate = NMDA. 4. Equimolar doses of AP5 abolished the toxicity produced by quinolinate and NMDA; toxicity to kainate and ibotenate was attenuated to approximately 40% of the toxin-alone condition. 5. The antagonistic properties of kynurenate were dose-dependent: equimolar kynurenate had no effect on quinolinate but attenuated the actions of ibotenate, kainate and NMDA; 2 x equimolar kynurenate had no effect on quinolinate or ibotenate but attenuated the toxicity of kainate and NMDA; and 3 x equimolar kynurenate had no effect on the toxicity of kainate or ibotenate, attenuated the actions of NMDA and abolished the toxic action of quinolinate. 6. The results are discussed in terms of the actions of the various toxins at different receptors, differentially sensitive to AP5 and kynurenate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677299      PMCID: PMC1917971          DOI: 10.1111/j.1476-5381.1991.tb12274.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Excitotoxic models for neurodegenerative disorders.

Authors:  R Schwarcz; A C Foster; E D French; W O Whetsell; C Köhler
Journal:  Life Sci       Date:  1984-07-02       Impact factor: 5.037

2.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid.

Authors:  M N Perkins; T W Stone
Journal:  Brain Res       Date:  1982-09-09       Impact factor: 3.252

3.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS.

Authors:  T W Stone; M N Perkins
Journal:  Eur J Pharmacol       Date:  1981-07-10       Impact factor: 4.432

4.  Susceptibility of rat neostriatum to damage by kainic acid: age dependence.

Authors:  J R Gaddy; M D Britt; D B Neill; H J Haigler
Journal:  Brain Res       Date:  1979-10-26       Impact factor: 3.252

5.  Quinolinic acid evokes [3H]acetylcholine release in striatal slices: mediation by NMDA-type excitatory amino acid receptors.

Authors:  J Lehmann; P Schaefer; J W Ferkany; J T Coyle
Journal:  Eur J Pharmacol       Date:  1983-12-09       Impact factor: 4.432

6.  Identification of quinolinic acid in rat and human brain tissue.

Authors:  M Wolfensberger; U Amsler; M Cuénod; A C Foster; W O Whetsell; R Schwarcz
Journal:  Neurosci Lett       Date:  1983-11-11       Impact factor: 3.046

7.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.

Authors:  R Schwarcz; W O Whetsell; R M Mangano
Journal:  Science       Date:  1983-01-21       Impact factor: 47.728

8.  On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds.

Authors:  A C Foster; J F Collins; R Schwarcz
Journal:  Neuropharmacology       Date:  1983-12       Impact factor: 5.250

9.  Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system.

Authors:  M N Perkins; T W Stone
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

10.  Quinolinic acid: regional variations in neuronal sensitivity.

Authors:  M N Perkins; T W Stone
Journal:  Brain Res       Date:  1983-01-17       Impact factor: 3.252

View more
  14 in total

1.  A lateralized deficit in morphine antinociception after unilateral inactivation of the central amygdala.

Authors:  B H Manning
Journal:  J Neurosci       Date:  1998-11-15       Impact factor: 6.167

2.  Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease.

Authors:  Carine Karachi; David Grabli; Frédéric A Bernard; Dominique Tandé; Nicolas Wattiez; Hayat Belaid; Eric Bardinet; Annick Prigent; Hans-Peter Nothacker; Stéphane Hunot; Andreas Hartmann; Stéphane Lehéricy; Etienne C Hirsch; Chantal François
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

3.  Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl.

Authors:  W M Behan; M McDonald; L G Darlington; T W Stone
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Differential action of NMDA antagonists on cholinergic neurotoxicity produced by N-methyl-D-aspartate and quinolinic acid.

Authors:  A C Pawley; S Flesher; R J Boegman; R J Beninger; K H Jhamandas
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

5.  Excitotoxicity of quinolinic acid: modulation by endogenous antagonists.

Authors:  K H Jhamandas; R J Boegman; R J Beninger; A F Miranda; K A Lipic
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

7.  Descending facilitatory pathways from the rostroventromedial medulla mediate naloxone-precipitated withdrawal in morphine-dependent rats.

Authors:  Louis P Vera-Portocarrero; Michael H Ossipov; Josephine Lai; Tamara King; Frank Porreca
Journal:  J Pain       Date:  2011-02-26       Impact factor: 5.820

8.  Inhibition by the adenosine analogue, (R-)-N6-phenylisopropyladenosine, of kainic acid neurotoxicity in rat hippocampus after systemic administration.

Authors:  D G MacGregor; T W Stone
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

9.  Prolonged responses in rat cerebellar Purkinje cells following activation of the granule cell layer: an intracellular in vitro and in vivo investigation.

Authors:  D Jaeger; J M Bower
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 10.  Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.

Authors:  Zsófia Majláth; Nóra Török; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.